Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

Key Inclusion Criteria:

• Hospitalized for acute decompensated heart failure.
• Systolic blood pressure ≥ 115 mmHg and ≤ 200 mmHg, and diastolic blood pressure ≥ 60 mmHg and ≤ 110 mmHg at screening
• Renally compromised.
• Female patients must be post-menopausal or surgically sterile.

Key Exclusion Criteria:

• Acute or suspected acute myocardial infarction (AMI) or troponin levels > 3X the upper limit of normal at the institution's local laboratory
• Cardiogenic shock
• Evidence of uncorrected volume or sodium depletion other clinical condition that would predispose the patient to adverse events
• Clinically significant aortic or mitral valve stenosis
• Temperature >38°C (oral or equivalent), sepsis or active infection requiring IV anti-microbial treatment
• ADHF due to significant arrhythmias
• Severe renal failure defined as creatinine clearance < 30 mL/min
• Current or planned ultrafiltration, hemofiltration, or dialysis
• Significant pulmonary disease
• Major neurologic event, including cerebrovascular events in the prior 60 days.
• Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns)
• Known hypersensitivity or allergy to natriuretic peptide or its components, nesiritide, other natriuretic peptides or related compounds